Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 5.23 is 64% below its 5-year average of 14.39, near the low end of its 5-year range (4.79–30.87).
As of the fiscal period ended Tuesday, June 30, 2026. 9.45% below its 12-month average of 5.77.
Reported quarterly quick ratio; no daily interpolation. Q1 FY2027 (2026-06-30): 5.23.
QUICK RATIO (ACID-TEST)
5.23
QUICK RATIO (ACID-TEST) AVG TTM
5.77
QUICK RATIO (ACID-TEST) AVG 3Y
9.60
QUICK RATIO (ACID-TEST) AVG 5Y
14.39
QUICK RATIO (ACID-TEST) AVG 10Y
15.75
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-9.45%
CURRENT VS 3Y AVG
-45.53%
CURRENT VS 5Y AVG
-63.67%
CURRENT VS 10Y AVG
-66.81%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
+56.05%
vs the sector median at left
Replimune Group, Inc.
Market Cap
$1.11B
Quick Ratio (Acid-Test)
5.23
TTM Avg
5.77
3Y Avg
9.60
5Y Avg
14.39
Market Cap
$1.11B
Quick Ratio (Acid-Test)
2.65
TTM Avg
2.17
3Y Avg
2.96
5Y Avg
3.83
Market Cap
$1.10B
Quick Ratio (Acid-Test)
4.03
TTM Avg
3.74
3Y Avg
4.48
5Y Avg
4.84
Market Cap
$1.13B
Quick Ratio (Acid-Test)
33.10
TTM Avg
10.19
3Y Avg
10.19
5Y Avg
10.19
Market Cap
$1.13B
Quick Ratio (Acid-Test)
2.08
TTM Avg
2.01
3Y Avg
3.15
5Y Avg
3.64
Market Cap
$1.10B
Quick Ratio (Acid-Test)
14.28
TTM Avg
10.49
3Y Avg
14.28
5Y Avg
14.28
Market Cap
$1.13B
Quick Ratio (Acid-Test)
1.38
TTM Avg
3.96
3Y Avg
6.78
5Y Avg
9.79
Market Cap
$1.09B
Quick Ratio (Acid-Test)
2.93
TTM Avg
3.33
3Y Avg
2.34
5Y Avg
2.11
Market Cap
$1.09B
Quick Ratio (Acid-Test)
11.59
TTM Avg
21.25
3Y Avg
14.51
5Y Avg
14.51
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Replimune Group, Inc. (REPL) | $1.11B | 5.23 | 5.77 | 9.60 | 14.39 |
| Tandem Diabetes Care, Inc. (TNDM)vs › | $1.11B | 2.65 | 2.17 | 2.96 | 3.83 |
| STAAR Surgical Company (STAA)vs › | $1.10B | 4.03 | 3.74 | 4.48 | 4.84 |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.13B | 33.10 | 10.19 | 10.19 | 10.19 |
| Harrow Health, Inc. (HROW)vs › | $1.13B | 2.08 | 2.01 | 3.15 | 3.64 |
| First Tracks Biotherapeutics Inc (TRAX)vs › | $1.10B | 14.28 | 10.49 | 14.28 | 14.28 |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.13B | 1.38 | 3.96 | 6.78 | 9.79 |
| OPKO Health, Inc. (OPK)vs › | $1.09B | 2.93 | 3.33 | 2.34 | 2.11 |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | 11.59 | 21.25 | 14.51 | 14.51 |
| IRadimed Corporation (IRMD)vs › | $1.08B | 8.13 | 7.23 | 6.69 | 8.24 |
Quick Ratio
5.23
Excludes inventory
Current Ratio
5.23
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 5.23 |
| 2026-03-31 | 4.79 |
| 2025-12-31 | 5.60 |
| 2025-09-30 | 6.31 |
| 2025-06-30 | 6.94 |
| 2025-03-31 | 7.95 |
| 2024-12-31 | 11.43 |
| 2024-09-30 | 10.11 |
| 2024-06-30 | 13.46 |
| 2024-03-31 | 10.72 |
| 2023-12-31 | 12.40 |
| 2023-09-30 | 12.76 |
| 2023-06-30 | 17.06 |
| 2023-03-31 | 17.52 |
| 2022-12-31 | 23.58 |
| 2022-09-30 | 16.12 |
| 2022-06-30 | 19.79 |
| 2022-03-31 | 19.46 |
| 2021-12-31 | 23.39 |
| 2021-09-30 | 26.71 |
| 2021-06-30 | 30.87 |
| 2021-03-31 | 33.25 |
| 2020-12-31 | 38.36 |
| 2020-09-30 | 19.47 |
| 2020-06-30 | 22.54 |
| 2020-03-31 | 14.68 |
| 2019-12-31 | 13.43 |
| 2019-09-30 | 9.85 |
| 2019-06-30 | 9.79 |
| 2019-03-31 | 14.51 |
| 2018-12-31 | 38.55 |
| 2018-09-30 | 41.16 |
| 2018-06-30 | 12.78 |
| 2018-03-31 | 12.99 |
| 2017-12-31 | 29.14 |
| 2017-09-30 | 0.00 |
| 2017-06-30 | 0.00 |
| 2017-03-31 | 11.29 |
